Skip to content

The Study on Impaired Cognitive Control Function in Older Adults with Mild Cognitive Impairment and Its Modulation by Transcranial Direct Current Stimulation

The Study on Impaired Cognitive Control Function in Older Adults with Mild Cognitive Impairment and Its Modulation by Transcranial Direct Current Stimulation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104930
Enrollment
Unknown
Registered
2025-06-25
Start date
2025-03-05
Completion date
Unknown
Last updated
2025-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment

Interventions

Active tDCS group:Anodal tDCS over the left dorsolateral prefrontal cortex (left DLPFC)
sham tDCS group:Sham tDCS over the left dorsolateral prefrontal cortex (left DLPFC)

Sponsors

Nanjing Brain Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 67 Years

Inclusion criteria

Inclusion criteria: All participants were informed of the experimental procedures and objectives and provided written informed consent. Participants met the following requirements: Right-handedness (assessed using the Chinese Handedness Inventory); Normal or corrected-to-normal vision (visual acuity = 0.8); No history of long-term psychotropic medication use. For MCI participants, additional criteria applied: Subjective cognitive complaints; Montreal Cognitive Assessment (MoCA) score < 26 (with 1-point adjustment for <= 12 years of education; maximum score = 30); Clinical Dementia Rating (CDR) score < 1, excluding dementia diagnosis; Preserved basic activities of daily living.

Exclusion criteria

Exclusion criteria: Severe hearing/communication impairments or physical disabilities; Current use of psychotropic medications or alcohol dependence; Major neuropsychiatric disorders (e.g., severe dementia, major depressive disorder, schizophrenia); Organic brain diseases (e.g., encephalitis, traumatic brain injury); Voluntary withdrawal or inability to complete the study; Contraindications for tDCS: Cardiac pacemakers or intracranial metal implantsl; History of epilepsy or stroke; Poor compliance or tDCS intolerance; tDCS treatment within 3 months or prior adverse events; Clinical deterioration during the study period.

Design outcomes

Primary

MeasureTime frame
inhibitory control;working memory updating;selective attention;

Countries

China

Contacts

Public ContactLuo Yuanrong

Nanjing Brain Hospital

lyrcordelia@163.com+86 181 0516 3585

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026